Rectal cancer drug trial of dostarlimab cures all patients: report
Fox News
A clinical trial of dostarlimab, done by Memorial Sloan Kettering Cancer Center, found the drug appears to have completely cured 12 patients of rectal cancer.
"Longer follow-up is needed to assess the duration of response." Ann W. Schmidt is a lifestyle reporter and editor for Fox News Digital.
That's according to a paper published on Sunday in the New England Journal of Medicine.
The patients took dostarlimab every three weeks for six months and had at least another six months of follow-up treatment, the paper said.
More Related News